Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors

This report addresses the determinants ofthe rate and extent of paclitaxelaccumulation in tumors. In a 2-dimensionalsystem such as monolayers where the drug isdirectly in contact with tumor cells, drugaccumulation is determined by theextracellular-to-intracellularconcentration gradient, the drug binding toextracellular and intracellularmacromolecules, the presence of the mdr1p-glycoprotein (Pgp), and thetime-dependent and drugconcentration-dependent changes in tubulinsand cell density. Intracellularpharmacokinetic models were developed todepict the effects of these parameters.Computer simulation results indicate thatat the clinically relevant concentrationrange of 1 to 1,000 nM, (a) the bindingaffinity and the number of intracellularsaturable drug binding sites are importantfor drug accumulation at low and highextracellular concentrations, respectively,(b) saturation in the drug binding to thehigh affinity intracellular binding sites(e.g., tubulin/microtubule) occurs atextracellular drug concentration above 100nM, (c) treatment with 1,000 nM paclitaxelfor ≥4 hr results in increased levels oftubulin/microtubule and consequentlyincreased intracellular drug accumulation,whereas the continued cell proliferationafter treatment with low drugconcentrations results in reducedintracellular accumulation, and (d)saturation of Pgp in mdr1-transfectedcells occurs at the high end of theclinically relevant concentration range. Ina 3-dimensional system such as the solidtumor histocultures, which contain tumorcells as well as stromal cells, the drugaccumulation into the inner cell layers isdetermined by the unique properties ofsolid tumors, including tumor cell densityand spatial arrangement of tumor andstromal tissues. Most interestingly, drugpenetration is modulated by thedrug-induced apoptosis; the reduced celldensity due to apoptosis results in anenhancement of the rate of drug penetrationinto the inner cell layers of solid tumors.In conclusion, the uptake, accumulation,and retention of paclitaxel in solid tumorsare determined by (a) factors that areindependent of biological changes in tumorcells induced by paclitaxel, i.e., ratio ofextracellular and intracellularconcentrations, and drug binding toextracellular and intracellularmacromolecules, and (b) factors that aredependent on the time- and drugconcentration-dependent biological changesinduced by paclitaxel, i.e., induction ofapoptosis, enhancement oftubulin/microtubule production, andinduction of Pgp expression.

[1]  S. Howell,et al.  Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. , 1994, British Journal of Cancer.

[2]  M. Wientjes,et al.  Pharmacodynamics of taxol in human head and neck tumors. , 1996, Cancer research.

[3]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[4]  H. Sasano,et al.  Potential of the histoculture drug-response assay to contribute to cancer patient survival. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  L. Grochow,et al.  High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. , 1987, Cancer treatment reports.

[6]  K. Bhalla,et al.  Characterization of a human myeloid leukemia cell line highly resistant to taxol. , 1994, Leukemia.

[7]  B. Sikic,et al.  Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). , 1996, Cancer research.

[8]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Peters,et al.  Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol , 1995, Cancer Chemotherapy and Pharmacology.

[10]  M. Bibby,et al.  Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. , 1997, European journal of cancer.

[11]  B. Monsarrat,et al.  Taxol: pharmacology, metabolism and clinical implications. , 1993, Cancer surveys.

[12]  Earl G. Adams,et al.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[13]  B. Baguley,et al.  Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS , 1995, Clinical and experimental pharmacology & physiology.

[14]  R. Hoffman,et al.  Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. , 1994, Archives of otolaryngology--head & neck surgery.

[15]  K. Tew,et al.  P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. , 1994, Journal of the National Cancer Institute.

[16]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[17]  E. Reed,et al.  Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer , 2004, Cancer Chemotherapy and Pharmacology.

[18]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Haber,et al.  Altered Expression of M2, the Class II -Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol Resistance (*) , 1995, The Journal of Biological Chemistry.

[20]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[21]  J. Carlsson,et al.  Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids , 2004, Cancer Chemotherapy and Pharmacology.

[22]  K. Cowan,et al.  Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. , 1990, Molecular pharmacology.

[23]  M. Wientjes,et al.  Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.

[24]  W D Lawrence,et al.  Paclitaxel‐induced apoptosis in MCF‐7 breast‐cancer cells , 1997, International journal of cancer.

[25]  D. Song,et al.  Binding of taxol to plastic and glass containers and protein under in vitro conditions. , 1996, Journal of pharmaceutical sciences.

[26]  V. Ling,et al.  P-glycoprotein, multidrug resistance and tumor progression , 1994, Cancer and Metastasis Reviews.

[27]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  Jörgen Carlsson,et al.  Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids , 2004, Cancer Chemotherapy and Pharmacology.

[29]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[30]  J. Manfredi,et al.  Taxol binds to cellular microtubules , 1982, The Journal of cell biology.

[31]  R. Hoffman,et al.  Clinical applications of the histoculture drug response assay. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.